Bispecific Antibodies Market (2026-2036)

The growth of this market is mainly driven by the strong commercial performance of established bispecifics in hemophilia and ophthalmology, the clinical success of T-cell engagers in hematologic and solid tumors, and large-scale licensing and investment by major pharmaceutical companies. However, cytokine release syndrome and neurotoxicity with associated treatment logistics, high prices and reimbursement barriers, manufacturing complexity, and clinical and regulatory uncertainty for new classes restrain the growth of this market.

Furthermore, PD-1 or PD-L1 by VEGF bispecifics, T-cell engagers for autoimmune diseases, and use in earlier lines of therapy with outpatient subcutaneous dosing are expected to offer growth opportunities for the stakeholders in this market. However, infections and long-term safety, limited efficacy in many solid tumors, delivery in community settings, and dependence on China-originated innovation amid geopolitical tension remain major challenges impacting the growth of this market. Additionally, the licensing wave for China-originated bispecifics, the rise of PD-1 by VEGF bispecifics, the shift toward subcutaneous and fixed-duration regimens, and expansion beyond oncology are prominent trends in this market.

The Bispecific Antibodies Market comprises engineered antibodies that bind two different antigens or two different epitopes, enabling mechanisms not possible with conventional monoclonal antibodies, such as redirecting immune cells to kill target cells, simultaneously blocking two disease pathways, or bridging proteins to restore biological function. The market covers immune cell engagers, primarily T-cell engagers that link CD3 on T cells to antigens such as CD19, CD20, BCMA, GPRC5D, DLL3, and gp100; dual ligand or receptor blocking antibodies, such as those targeting Ang-2 and VEGF-A, EGFR and MET, and PD-1 or PD-L1 and VEGF; and bridging and factor-mimetic antibodies, such as those mimicking coagulation factor VIII. Formats include IgG-like antibodies, fragment-based designs, and trispecific and multispecific molecules. Therapeutic areas include hemophilia, ophthalmology, oncology, and autoimmune and inflammatory diseases. Bispecific antibody-drug conjugates are analyzed separately in ADC markets. The ecosystem spans pharmaceutical and biotechnology companies, antibody engineering platform providers, contract manufacturers, hospitals, specialty clinics, payers, and regulators.

Bispecific antibodies have moved from niche to mainstream. Roche's Hemlibra, approved in 2017 for hemophilia A, generated CHF 1.2 billion in the first quarter of 2025, up 11%, and Roche's Vabysmo, approved in 2022 for neovascular age-related macular degeneration and diabetic macular edema, generated CHF 1.0 billion in the quarter, up 18%, with both ranked among Roche's top growth drivers through the first nine months of 2025. In oncology, Amgen's Blincyto, first approved in 2014, grew 45% to USD 384 million in the second quarter of 2025, and a wave of T-cell engagers has been approved in recent years, including Johnson & Johnson's Tecvayli and Talvey and Pfizer's Elrexfio in multiple myeloma, Roche's Columvi and Lunsumio and Genmab and AbbVie's Epkinly in lymphoma, Amgen's Imdelltra in small cell lung cancer, and Regeneron's Lynozyfic in multiple myeloma, along with Johnson & Johnson's EGFR by MET bispecific Rybrevant in lung cancer and Jazz and Zymeworks' HER2 bispecific Ziihera in biliary tract cancer.

A new class of PD-1 or PD-L1 by VEGF bispecifics has triggered major investment. Akeso's ivonescimab outperformed pembrolizumab on progression-free survival in a Phase 3 trial in China in 2024, and Summit Therapeutics licensed it for major Western markets in 2022 with an upfront payment of USD 500 million. In 2025, Pfizer licensed 3SBio's PD-1 by VEGF bispecific with USD 1.25 billion upfront, and Bristol Myers Squibb agreed to co-develop BioNTech's PD-L1 by VEGF bispecific, originally from China's Biotheus, with USD 1.5 billion upfront in a deal worth up to about USD 11 billion, following Merck & Co.'s 2024 license of LaNova's PD-1 by VEGF bispecific with USD 588 million upfront.

Challenges remain. T-cell engagers can cause cytokine release syndrome and neurotoxicity, requiring step-up dosing, monitoring, and often hospitalization, and BCMA-targeted T-cell engagers are associated with serious infections. Bispecifics are expensive and complex to manufacture, and new classes face clinical uncertainty, as when Summit's global HARMONi trial of ivonescimab in EGFR-mutated lung cancer met its progression-free survival endpoint in 2025 but did not show a statistically significant overall survival benefit. Nevertheless, rising cancer incidence, which the International Agency for Research on Cancer projects will exceed 35 million new cases annually by 2050, and expansion into autoimmune diseases support strong long-term growth.